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Abstract 
Purpose: To systematically analyze the efficacy of azithromycin and benzathine penicillin in early 
syphilis, and provide guidance for diagnosis and treatment. 
Methods: Databases were searched for randomized controlled trials (RCTs) and control studies 
according to keywords, and inclusion and exclusion criteria. Related documents and meeting records 
were also searched manually to extract study types, basic information of study objects, intervention 
measurements and study results, and evaluation of the quality of the methodology used. 
Results: Three studies were excluded from the review. The quality evaluation was B grade, and 
heterogenicity was good. We adopted a fixed effect model to conduct the meta-analysis. There was no 
significant difference in the cure rate between azithromycin and benzathine penicillin administered for 6 
months. The ORs for 3 time points were 0.96 (95% CI = 0.71, 1.29), 0.01 (95% CI = -0.05, 0.06), and 
0.04 (95% CI = -0.02, 0.11; p < 0.05). There were no significant differences in the incidence of adverse 
events among the three studies. 
Conclusion: There was no apparent difference in the efficacy of azithromycin and benzathine penicillin 
in early syphilis. The advantages of azithromycin included good compliance, a long half-life, and a high 
economic benefit.  
 
Keywords: Early syphilis, Azithromycin, Benzathine penicillin, Curative effect 
 
This is an Open Access article that uses a funding model which does not charge readers or their institutions 
for access and distributed under the terms of the Creative Commons Attribution License 
(http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly credited. 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




The effectiveness of a single dose of benzathine 
penicillin for early syphilis by muscle injection 
has been confirmed because of the low cost and 
good compliance; however, the disadvantages 
include pain caused by a high-dose deep 
intramuscular injection, drug allergy, disposable 
injection equipment, related personnel training, 
and the risk for transmission of bloodborne 
disease pathogens. It is thus necessary to 
research and develop an effective and well-
tolerated single dose oral medication [1-3]. 
Azithromycin is a macrolide antibiotic which has 
a tissue half-life of 70 h. It has been reported that 
azithromycin can effectively control infections 
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involving Bedsonia trachomatis, Neisseria 
gonorrhoeae, and Haemophilus ducreyi [4,5]. 
Therefore, we conducted a systematic review on 
the curative effect of azithromycin and 
benzathine penicillin on early syphilis based on 






The following keywords were searched for in this 
study: “early syphilis;” “benzathine penicillin;” and 
“azithromycin.” The timeframe for the selected 
documents was January 1975-December 2015. 
The Medline, Embase, and Cochrane Library 
databases were searched. The search also 





In the current study, publications were 
considered eligible for inclusion if the following 
inclusion criteria were met: (1) randomized 
controlled trial; (2) English literature; (3) oral 
azithromycin treatment; (4) > 18 years of age; 
and (5) evaluated the cure rate, and the skin rash 
improved or faded and the rapid plasma reagin 
test was negative during follow-up evaluation. All 
of the relevant content in this study was made 
available and agreed to by the Ethics Committee 
of our hospital. The literature was independently 
screened by two authors. When the authors 
disagreed, the difference was settled through 
negotiation or a third author participated in the 
deliberation and decision if necessary. 
 
Data extraction  
 
Data extraction was independently performed by 
two researchers from the included studies.  
The cases were separately analyzed for 
serologic cure and adverse reactions. Intention-
to-treat analysis was used to calculate the loss 




The odds ratio (OR) was calculated for 
successfully treating early syphilis by 
azithromycin and benzathine penicillin in each 
study. Studies with incomplete follow-up records 
were excluded. Statistical significance is 
represented as the OR and 95% confidence 
interval (CI). We used a fixed effects model and 
unified OR values that were detected by chi-
square tests. Errors might exist in the evaluation 
results due to hierarchical meta-analysis. Data 
were stratified by different subgroups, including 
the follow-up time point, different stages of early 
syphilis, and different doses of azithromycin. P-







There were three documents excluded based on 
keywords, inclusion criteria, and exclusion 
criteria. To evaluate the generation of assigned 
sequences in randomized controlled trials, a 
blinded method, integrity of data statistics, and 
selective reporting according to risk bias 
assessment methods were used as reported in 
the literature. The results showed that the 
research quality evaluation of the three studies 
were B grade. There were 919 patients included 
in the analysis from studies published between 
2001 and 2010 with follow-up 1, 3, 6, and 9 
months after treatment. Follow-up content 
included adverse events after treatment and 
serology detection. The flow figure of document 
selection is shown in Figure 1. The content 
abstract of the included documents is shown in 
Table 1. 
 
Forest map meta-analysis  
 
The time point of selection was 3, 6, and 9 
months after treatment. The data from three 
studies were compared and analyzed. 
Heterogeneity analysis showed a p > 0.05 of the 
three times points. A fixed effect model was used 
for meta-analysis. The OR value of the 3 times 
points was 0.96 (95% CI = 0.71, 1.29), 0.01 
(95% CI = -0.05, 0.06), and 0.04 (95% CI = -
0.02, 0.11; p > 0.05). Because diamond and 
vertical lines intersected with each other, there 
was no significant difference in the efficacy 
among the 3 drugs 2 and 6 months after 
treatment. One study had 9 months of healing 
data missing and the bias of the diamond was 
apparent. Therefore, a further analysis for the 
cure rate 9 months after treatment was 
necessary (Figure 2). 
 
Time of adverse reactions  
 
With respect to adverse reactions, azithromycin-
associated gastrointestinal discomfort was a 
common phenomenon, which always occurred 1 
- 2 weeks after treatment. The main adverse 
events in patients were fever, vomiting, diarrhea, 
and ulcers. There was no significant difference in 
the incidence of adverse reactions for two drugs, 
which occurred in the included studies. The early 
reports of Hook showed that although the 
azithromycin-induced indigestion event rate was 
Li et al 





Figure 1: Document retrieval and flow figure for document selection 
 
5 times that of benzathine penicillin; there was no 
obvious different between azithromycin and 
benzathine penicillin (RR = 4.75; 95% CI = 0.67–
33.9; P = 0.09) [6-8]. The funnel chart analysis 
for published bias could not be carried out 





Based on the current meta-analysis, there was 
no significant difference in the 6-month cure rate 
between azithromycin and benzathine penicillin 
in patients with early syphilis. The interference of 
system and random error led to bias in the 
results. The analysis of follow-up time, staging of 
disease, dosage of azithromycin, and other 
variables showed that obvious systematic error 
did not exist. The results of pooled analysis were 
well-distributed, which implied that the magnitude 
of the random error was not as large as 
expected. Azithromycin did not show a higher 
cure rate than benzathine penicillin, which was 
consistent with past studies [9]. At present, there 
is still a lack of data on the cure rate of syphilis in 
the second stage and latent phase. Therefore, 
future studies should be conducted to improve 
the procedure. 
 
A random experiment directly comparing the side 
effects between azithromycin and benzathine 
penicillin, including Jarisch–Herxheiner reaction 
and digestive discomfort, did not exist in past 
studies [10,11]. Some studies have reported that 
the adverse reaction rate of azithromycin is five 
times that of benzathine penicillin, but there was 
no apparent statistical difference [9,11]. Patient 
compliance was one of the most important 
factors in considering treatment decisions. 
Benzathine penicillin is always dosed twice daily, 
while azithromycin is a once per day regimen. 
Because patients tend to be prescribed 
azithromycin and there was no significant 
difference in the effect of two drugs, some 
studies regard azithromycin as the preferred drug 
[12,13].  
 
Combined with the characteristics of the 60-h 
half-life of azithromycin, satisfactory serum 
concentrations could be maintained by taking 
azithromycin one time per day. There was no 
significant difference between the effect of early 
syphilis and benzathine penicillin based on the 
analysis of the ratio of different doses of 
azithromycin. It has been suggested that 
treatment with penicillin and partial compliance 
can effectively control early syphilis; however, 
dose-response tests should confirm the findings. 
 
The clinical cost differences between single and 
repeated doses always play an important role in 
therapeutic decision-making under the premise 
of limited resources. The treatment of 
uncomplicated genital syphilis infections is 
controversial [14]. Azithromycin has been 
patented for > 10 years in the United States, and 
benzathine penicillin is inexpensive. The 
corresponding cost for benzathine penicillin also  
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Table 1: Abstract of included articles 
 





74 patients were divided into three groups: benzathine penicillin group, 2.0 g azithromycin 
group and 4.0 g azithromycin group. The overall male and female proportion was 11:9. The 
average age of patients in these three groups was 29 years (range, 18 - 49 years), 33 years 
(range, 18 - 56 years), and 28 years (range, 18 - 49 years). The follow-up time of 81 % 
patients was equal to or greater than 3 months. The study time period was from October 
1995 to December 1997. 
Intervention 
measurement 
The patients in these three groups received 2.4 million unit intramuscular injection of 
benzathine penicillin 1 or 2 times, took 2.0g azithromycin orally 1 or 2 times, and the time 
interval was about 1 week. Follow-up evaluations occurred 1 week, 2 weeks, and 1, 3, 6, 9, 
and 12 months after treatment. The follow-up content included sexual history, serologic 
evaluation, and evaluation of the recurrence of syphilis. 
Results 
 
94% of patients (16/17) in the azithromycin (2.0g) group had serologic improvement. 
Compared with the benzathine penicillin group, there was no obvious difference in the cure 
rate until the end of follow-up (RR=0.97; 95% CI, 0.74–1.27; P=0.75). 83% of patients in the 
azithromycin (2.0g) group had serologic improvement, compared with the benzathine 
penicillin group, there was no obvious difference in the cure rate (RR=0.88; 95% CI, 0.72–
1.08; P=0.95). The probability of gastrointestinal discomfort of the patients in the 
azithromycin group was higher compared with benzathine penicillin; the probability of 
adverse events for these two drugs was 17% and 24% respectively. 




The study time period was September - March 2000. There were 328 patients, and the 
average age was 27 years (range, 15 - 60 years). The male-to-female ratio was 93:235; 
50.3 % of the patients received benzathine penicillin treatment and 49.7 % of the patients 
received azithromycin treatment. 
Intervention 
measurement 
Patients in the 2 groups received a 2.4 M U intramuscular injection of benzathine penicillin 
or azithromycin 2.0g orally. The follow-up time points were 3, 6, and 9 months after 
treatment. The follow-up content included serologic evaluation and adverse events. 
Results 
 
The cure rate of benzathine penicillin and azithromycin at three times points were as 
follows:  
59.4% (95% CI, 51.8-67.1) versus 59.5 (95% CI, 51.8-67.3); 85.5% (95% CI, 79.4-90.6) 
versus 81.5 (95% CI, 74.8-87.4); and 98.3% (95% CI, 94.5-99.7) versus 96.5 (95% CI, 92.0-
98.8). There was no obvious difference in the incidence of adverse events between the two 
groups. 




The study time period was June 2000-March 2007. There were 517 patients; the average 
age was 27 years, and the male-to-female ratio was 313:204. 262 patients received 
benzathine penicillin treatment and 255 patients received azithromycin treatment. 
Intervention 
measurement 
Two groups of patients received a 2.4 M U intramuscular injection of benzathine penicillin 
and 2.0g of oral azithromycin treatment. The follow-up time points were 1 week, 2 weeks, 
and 3 months and 6 months after treatment. The follow-up content included serologic 
evaluation and adverse events. 
Results 
 
By the end of the follow-up period, the percentage of azithromycin and benzathine penicillin 
that reached the serologic cure standard was 77.6% and 78.5%, respectively (lower limit of 
the 95% CI, 7.2%). The corresponding incidence of adverse events was 61.5% and 46.3%, 
respectively. 
 
includes the cost of a needle and syringe. The 
results of two studies [15, 16] on the cost 
effectiveness of antibiotics showed that 
azithromycin had a superior cost-benefit, while 
statistical analysis of the cost of the 
corresponding drugs has not been performed in 
published studies. Considering the assumption is 
not accurate, a comprehensive cost-benefit 
analysis should be conducted. 
 
Compared with the 2.4 M U dose of benzathine 
penicillin, azithromycin is effective in controlling 
early syphilis. There were no obvious differences 
in adverse reactions. Therefore, a further 
dosage-reaction test evaluation plan for 
azithromycin is needed. Combined with other 
related study results, when the hidden trouble 
exists or the patients cannot tolerate during 
benzathine penicillin use. Azithromycin can be 
regarded as a good replacement therapy drug. 
Therefore, it is necessary to conduct a further 
study on the effect of benzathine penicillin in 
early syphilis, enhance the accuracy of the 
results, and provide guiding clinical significance. 
 
However, there were some limitations in this 
study, including the insufficient inclusion of the 
literature and lack of strength of evidence. 
Therefore, it is necessary to compare and 





The findings show that there is no obvious 
difference between azithromycin and benzathine 
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Figure 2. Forest map meta-analysis of the three times points 
 
penicillin in terms of their therapeutic effect on 
early syphilis. However, azithromycin has the 
advantages of good compliance, long half-life 
and lower cost. Therefore, its likelihood for 
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